Is Mobotinib/Mobotinib a capsule? What is API

Mobocertinib/Mobocertinib is an oral targeted drug used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC), especially for adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. This type of lung cancer usually shows disease progression after platinum-based chemotherapy. Therefore, the application of moboxetinib provides a new treatment option for these patients, which can specifically target relevant mutations and improve the therapeutic effect.

In the process of drug development, mobosetinib is a kinase inhibitor whose main mechanism of action is to selectively inhibit the activity ofEGFR, thereby preventing the proliferation and spread of cancer cells. Scientists have conducted in-depth research on the design of its molecule to ensure that it can effectively bind EGFR and intervene in abnormal signaling caused by mutations. Specifically, the chemical structure of mobotinib succinate is complex, and its chemical name is prop-2-yl 2-[5-(acrylamino)-4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxyanilino ]-4-(1-Methyl-1H-indol-3-yl)pyrimidine-5-carboxylic acid succinate, the molecular formula is C32H39N7O4+C4H6O4 (succinate), and the relative molecular weight is 703.8g/mol.

In terms of dosage form, mobosetinib is provided in capsule form, which is convenient for patients to take orally. Each capsule contains40 mg of the active ingredient Mobocertinib, equivalent to 48.06 mg of Mobocertinib succinate. In addition, the composition of these capsules does not contain other inactive ingredients, making the effect of the drug more focused. The capsule shell is composed of gelatin and titanium dioxide. These ingredients are widely used in the medical field to ensure the release and absorption of drugs in the body.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a91500-a944-4cb8-b4a8-ae278bcf728d